Have a feature idea you'd love to see implemented?
Let us know!
ZNTL Zentalis Pharmaceuticals Inc
Price (delayed)
$3.1
Market cap
$220.43M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.72
Enterprise value
$222.1M
Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. The Company is developing a broad pipeline of
Highlights
Zentalis Pharmaceuticals's EPS has increased by 43% YoY and by 18% from the previous quarter
Zentalis Pharmaceuticals's net income has increased by 32% YoY and by 11% from the previous quarter
Zentalis Pharmaceuticals's quick ratio has decreased by 40% YoY and by 28% from the previous quarter
ZNTL's equity is down by 27% YoY and by 17% from the previous quarter
Key stats
What are the main financial stats of ZNTL
Market
Valuations
Earnings
Shares outstanding
71.11M
Market cap
$220.43M
Enterprise value
$222.1M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.58
Price to sales (P/S)
5.43
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
5.48
Revenue
$40.56M
EBIT
-$194.35M
EBITDA
-$193.01M
Free cash flow
-$166.8M
Per share
Balance sheet
Liquidity
EPS
-$2.72
Free cash flow per share
-$2.35
Book value per share
$5.39
Revenue per share
$0.57
TBVPS
$6.87
Total assets
$491.68M
Total liabilities
$109.1M
Debt
$41.32M
Equity
$382.58M
Working capital
$372.92M
Debt to equity
0.11
Current ratio
6.59
Quick ratio
6.43
Net debt/EBITDA
-0.01
Margins
Efficiency
Dividend
EBITDA margin
-475.9%
Gross margin
100%
Net margin
-479.9%
Operating margin
-543.8%
Return on assets
-35.6%
Return on equity
-44.2%
Return on invested capital
-41.6%
Return on capital employed
-45.7%
Return on sales
-479.2%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ZNTL stock price
How has the Zentalis Pharmaceuticals stock price performed over time
Intraday
-6.63%
1 week
3.33%
1 month
-22.89%
1 year
-81.4%
YTD
-79.54%
QTD
-15.76%
Financial performance
How have Zentalis Pharmaceuticals's revenue and profit performed over time
Revenue
$40.56M
Gross profit
$40.56M
Operating income
-$220.55M
Net income
-$194.65M
Gross margin
100%
Net margin
-479.9%
Zentalis Pharmaceuticals's net income has increased by 32% YoY and by 11% from the previous quarter
The operating income has grown by 20% YoY and by 15% from the previous quarter
The operating margin is up by 15% since the previous quarter
The company's net margin rose by 11% QoQ
Growth
What is Zentalis Pharmaceuticals's growth rate over time
Valuation
What is Zentalis Pharmaceuticals stock price valuation
P/E
N/A
P/B
0.58
P/S
5.43
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
5.48
Zentalis Pharmaceuticals's EPS has increased by 43% YoY and by 18% from the previous quarter
The P/B is 88% less than the 5-year quarterly average of 4.9 and 72% less than the last 4 quarters average of 2.1
ZNTL's equity is down by 27% YoY and by 17% from the previous quarter
Efficiency
How efficient is Zentalis Pharmaceuticals business performance
ZNTL's ROIC is up by 39% year-on-year and by 15% since the previous quarter
The ROA is up by 32% year-on-year and by 6% since the previous quarter
The ROE rose by 31% year-on-year and by 4.1% since the previous quarter
Zentalis Pharmaceuticals's ROS has increased by 11% from the previous quarter
Dividends
What is ZNTL's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ZNTL.
Financial health
How did Zentalis Pharmaceuticals financials performed over time
Zentalis Pharmaceuticals's quick ratio has decreased by 40% YoY and by 28% from the previous quarter
The current ratio has decreased by 40% YoY and by 28% from the previous quarter
The company's debt is 89% lower than its equity
The debt to equity has grown by 38% year-on-year and by 22% since the previous quarter
ZNTL's equity is down by 27% YoY and by 17% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.